Evidence map›Paper›PMID 33556134›Full record

ArticlePloS one2021

Physicochemical properties and formulation development of a novel compound inhibiting Staphylococcus aureus biofilm formation.

Nan Wang, Feng Qi, Haqing Yu, Bryan D Yestrepsky, Scott D Larsen, Honglan Shi, Juan Ji, David W Anderson, Hao Li, Hongmin Sun

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nan WangDepartment of Mechanical and Aerospace Engineering, University of Missouri, Columbia, Missouri, United States of America.
Feng QiDepartment of Mechanical and Aerospace Engineering, University of Missouri, Columbia, Missouri, United States of America.
Haqing YuDivision of Cardiovascular Medicine, Department of Medicine, University of Missouri, Columbia, Missouri, United States of America.
Bryan D YestrepskyVahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, United States of America.
Scott D LarsenVahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, United States of America.
Honglan ShiDepartment of Chemistry, Missouri University of Science and Technology, Rolla, Missouri, United States of America.
Juan JiDepartment of Biochemistry, University of Missouri, Columbia, Missouri, United States of America.
David W AndersonIvogen Inc. (Subsidiary of Nanova, Inc.), Columbia, Missouri, United States of America.ORCID 0000-0001-9650-6150
Hao LiDepartment of Mechanical and Aerospace Engineering, University of Missouri, Columbia, Missouri, United States of America.
Hongmin SunDivision of Cardiovascular Medicine, Department of Medicine, University of Missouri, Columbia, Missouri, United States of America.ORCID 0000-0003-4545-2417

Funding

INTERDEPARTMENTAL TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007767 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ISOM, LORI L. · 1985 to 2019
$10.2M
NIGMS NIH HHS T32 GM007767
6 · The paper itself

Abstract

The emergence of antibiotic resistance over the past several decades has given urgency to new antibacterial strategies that apply less selective pressure. A new class of anti-virulence compounds were developed that are active against methicillin-resistant Staphylococcus aureus (MRSA), by inhibiting bacterial virulence without hindering their growth to reduce the selective pressure for resistance development. One of the compounds CCG-211790 has demonstrated potent anti-biofilm activity against MRSA. This new class of anti-virulence compounds inhibited the gene expression of virulence factors involved in biofilm formation and disrupted the biofilm structures. In this study, the physicochemical properties of CCG-211790, including morphology, solubility in pure water or in water containing sodium dodecyl sulfate, solubility in organic solvents, and stability with respect to pH were investigated for the first time. Furthermore, a topical formulation was developed to enhance the therapeutic potential of the compound. The formulation demonstrated acceptable properties for drug release, viscosity, pH, cosmetic elegance and stability of over nine months.

Indexed as

Anti-Bacterial AgentsBiofilmsStaphylococcus aureusVirulence FactorsAnti-Bacterial AgentsVirulence Factors

Identifiers

PMID33556134
PMCPMC7870075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.